Mechanistic medicine: Novel strategies for clinical trials

Autoimmunity

Volumn 43, Issue 7, 2010, Pages 560-571

  Itano, Andrea A ^a   Sims, Martin J ^a   Siu, Gerald ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Autoimmune; clinical trial; dose guiding; lymphocytes; pharmacodynamic assays

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ADALIMUMAB; BELIMUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB;

AUTOIMMUNE DISEASE; CELL ACTIVITY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MEDICINE; NONHUMAN; PATIENT CODING; PEMPHIGUS VULGARIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 77957981838     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916931003674782     Document Type: Review

References (55)

1. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of Rituximab in autoimmune diseases. Int Immunopharmacol 2009;9:10-25.
2. Crews S, Griffin J, Huang H, Calame K, Hood L. A single VH gene segment encodes the immune response to phosphor-ylcholine: Somatic mutation is correlated with the class of the antibody. Cell 1981;25:59-66.
3. Kumar V, Tabibiazar R, Geysen HM, Sercarz E. Immunodo-minant framework region3peptide from TCRVbeta 8.2 chain controls murine experimental autoimmune encephalomyelitis. J Immunol 1995;154:1941-1950.
4. Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B-cell tolerance. J Clin Invest 2001;108:1061-1070.
5. Cappione AJ, Pugh-Bernard AE, Anolik JH, Sanz I. Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. J Immunol 2004;172:4298-4307.
6. Cappione A, 3rd, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, Sanz I. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005;115:3205-3216.
7. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl J Med 1999;340: 253-259.
8. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. New Engl J Med 2000;343:1594-1602.
9. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65:753-759.
10. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W. Belimumab study group. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (B-LyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109.
11. Cancro MP, D'Cruz DP, Khamashta MA. The role of B-lymphocyte stimulator (B-LyS) in systemic lupus erythema-tosus. J Clin Invest 2009;119:1066-1073.
12. Zekavat G, Rostami SY, Badkerhanian A, Parsons RF, Koeberlein B, Yu M, Ward CD, Migone TS, Yu L, Eisenbarth GS, Cancro MP, Naji A, Noorchashm H. In vivo B-LyS/BAFF neutralization ameliorates islet-directed auto-immunity in nonobese diabetic mice. J Immunol 2008;181: 8133-8144.
13. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192(10):1453-1466.
14. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20(4):441-453.
15. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20: 785-798.
16. Zarkhin V, Li L, Sarwal MM. BAFF may modulate the rate of B-cell repopulation after Rituximab therapy for acute renal transplant rejection. Transplantation 2009;88: 1229-1230.
17. Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in Pe. vulgaris. J Invest Dermatol 2009;129:2202-2210.
18. West K. CP-690550, a Jak3 inhibitor as an immunosuppres-sant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Invest Drugs 2009;10:491-504.
19. Borie DC, O'Shea JJ, Changelian PS. Jak3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 2004;10:532-541.
20. Quaedackers ME, Mol W, Korevaar SS, van Gurp EA, van Ijcken WF, Chan G, Weimar W, Baan CC. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the Jak/STAT pathway in kidney transplant patients. Transplantation 2009;88(8):1002-1009.
21. Manshouri T, Quintás-Cardama A, Nussenzveig RH, Gaikwad A, Estrov Z, Prchal J, Cortes JE, Kantarjian HM, Verstovsek S. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the Jak2V617F mutation. Cancer Sci 2008;99:1265-1273.
22. Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000;12: 557-562.
23. Hirano T. Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. Int Immunopharmacol 2007;7:3-22.
24. Eming R, Büdinger L, Riechers R, Christensen O, Bohlen H, Kalish R, Hertl M. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and Pe vulgaris by enzyme-linked immunospot assay. Br J Dermatol 2000;143: 1279-1282.
25. Yamagami J, Takahashi H, Ota T, Amagai M. Genetic characterization of human Dsg3-specific B cells isolated by flow cytometry from the peripheral blood of patients with Pe. vulgaris. J Dermatol Sci 2008;52:98-107.
26. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in Pe. vulgaris. J Invest Dermatol 2008;128:2850-2858.
27. Metz DP, MohnD, Zhang M, Horan T, Kim H,Deshpande R, Jacobsen F, Shen WD, Zhang L, Doellgast G, Narayanan A, Dalphin M, Kuchimanchi KR, Horner M, Chung J, Siu G. Defining dose-response relationships in the therapeutic blockade of B7RP-1-dependent immune responses. Eur J Pharmacol 2009;610:110-118.
28. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103: 1243-1252.
29. Mathis D, Benoist C. AIRE. Ann Rev Immunol 2009;27: 287-312.
30. Su MA, Anderson MS. Monogenic autoimmune diseases: Insights into self-tolerance. Pediat Res 2009;65:20R-25R.
31. Bi LL, Pan G, Atkinson TP, Zheng L, Dale JK, Makris C, Reddy V, McDonald JM, Siegel RM, Puck JM, Lenardo MJ, Straus SE. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib. BMC Med Genet 2007;8:41.
32. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, entero-pathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20.
33. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrino-pathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-21.
34. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D. Projection of an immunological self shadow within the thymus by the AIRE protein. Science 2002;298: 1395-1401.
35. Ramsey C, Bukrinsky A, Peltonen L. Systematic mutagenesis of the functional domains of AIRE reveals their role in intracellular targeting. Human Mol Genet 2002;11: 3299-3308.
36. Devoss JJ, Shum AK, Johannes KP, Lu W, Krawisz AK, Wang P, Yang T, Leclair NP, Austin C, Strauss EC, Anderson MS. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. J Immunol 2008;181:4072-4079.
37. Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheumat 1993;36:1305-1314.
38. Van den Berg WB, Joosten LA, Helsen M, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exper Immun 1994;95: 237-243. (Pubitemid 24207133)
39. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB. 990145 Study Group. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004;63:1062-1068.
40. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheumat 2004;50:607-612.
41. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-1486.
42. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, Ardura M, Chung W, Smith E, Wise C, Palucka K, Ramilo O, Punaro M, Banchereau J, Pascual V. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007;204:2131-2144.
43. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P. International league of associations for rheumatology. International league of associations for rheumatology classification of juvenile idio-pathic arthritis: Second revision, Edmonton, 2001. J Rheu-matol 2004;31:390-392.
44. Pascual V, Allantaz F, Patel P, Palucka AK, Chaussabel D, Banchereau J. How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev 2008;223:39-59.
45. Amel-Kashipaz MR, Huggins ML, Lanyon P, Robins A, Todd I, Powell RJ. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the Jak/STAT pathway in kidney transplant patients. J Autoimmun 2001;17:155-163.
46. Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, Scheinecker C. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008;20: 861-868.
47. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM, CD69 HLA-DR. and the IL-2R identify persistently activated T cells in Ps vulgaris lesional skin: Blood and skin comparisons by flow cytometry. J Autoimmun 2000;14:63-78.
48. De Miguel S, Jover JA, Vadillo C, Judez E, Loza E, Fernandez-Gutierrez B. B cell activation in rheumatoid arthritis patients under Infliximab treatment. Clin Exp Rheumatol 2003;21: 726-732.
49. Ikeda K, Yamaguchi K, Tanaka T, Mizuno Y, Hijikata A, Ohara O, Takada H, Kusuhara K, Hara T. Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease. Clin Exp Immunol 2010;160:246-255.
50. Al-Shukaili A, Al-Kaabi J, Hassan B. A comparative study of interleukin-1b production and p2 £ 7 expression after ATP stimulation by peripheral blood mononuclear cells isolated from rheumatoid arthritis patients and normal healthy controls. Inflammation 2008;31:84-90.
51. Ráki M, Fallang LE, Brottveit M, Bergseng E, Quarsten H, Lundin KE, Sollid LM. Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients. Proc Natl Acad Sci USA 2007;104:2831-2836.
52. Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, KarlssonL, Fung-Leung WP. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol 2004;142:161-171.
53. Chirumbolo S, Conforti A, Ortolani R, Vella A, Marzotto M, Bellavite P. Stimulus-specific regulation of CD63 and CD203c membrane expression in human basophils by the flavonoid quercetin. Int Immunopharmacol 2010;10:183-192.
54. Zoog SJ, Itano A, Trueblood E, Pacheco E, Zhou L, Zhang X, Ferbas J, Ng GY, Juan G. Antagonists of CD117 (cKit) signaling inhibit mast cell accumulation in healing skin wounds. Cytometry A 2009;75:189-198.
55. Johnson C, Walls RS, Ruwoldt A. Delayed hypersensitivity to tetanus toxoid in man: In vivo and in vitro studies. Pathology 1983;15:369-372.